Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02391233 · ClinicalTrials.gov registry record · NA
Multimedia WORTH With Black Drug-Involved Women on Probation
A NA study of HIV and Drug Use, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 354
- Enrollment target
- 1
- Study location
NCT02391233: Completed NA study of HIV and Drug Use, sponsored by Columbia University.
NCT02391233 is a NA study of HIV and Drug Use that has completed, run by Columbia University. The registered enrollment target is 354 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02391233, a NA study of HIV and Drug Use, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 354 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is a randomized controlled trial (RCT) that will rigorously evaluate the effectiveness and cost-effectiveness of delivering a multimedia evidence-based intervention (WORTH) and streamlined HIV testing to prevent human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs) with Black/African-American (hereafter referred to as Black) women drug users in probation sites in New York City (NYC), compared to streamlined HIV testing alone. Repeated assessments will occur at baseline and 3, 6, and 12-months post intervention. The primary outcomes will be to reduce cumulative incidence of biologically confirmed STIs (i.e., Chlamydia, gonorrhea and trichomonas and the number of unprotected sex acts.
Conditions Studied
Interventions
- BEHAVIORAL E-WORTH
- BEHAVIORAL Streamlined HIV Testing
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2015-11-15 |
| Est. Completion | 2019-09 |
| Phase | NA |
What the finished NCT02391233 record still lists
NCT02391233 is an interventional study that assigns participants to a tested intervention. The registered 354 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (19% lower).
The record links to 6 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which E-WORTH is the first listed.
NCT02391233 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02391233 about?
NCT02391233 is a clinical study titled "Multimedia WORTH With Black Drug-Involved Women on Probation". The proposed study is a randomized controlled trial (RCT) that will rigorously evaluate the effectiveness and cost-effectiveness of delivering a multimedia evidence-based intervention (WORTH) and streamlined HIV testing to prevent human immunodeficiency virus (HIV) and other sexually transmitted inf...
What is the current status of trial NCT02391233?
This trial is currently completed. It is a NA study. The enrollment target is 354 participants. The study started on 2015-11-15. Estimated completion is 2019-09.
What conditions does trial NCT02391233 study?
This clinical trial studies the following conditions: HIV, Drug Use, Sexually Transmitted Infections, Gonorrhea, Chlamydia Trachomatis.
What interventions are being tested in trial NCT02391233?
The interventions under investigation include: E-WORTH (BEHAVIORAL), Streamlined HIV Testing (BEHAVIORAL).
Who is sponsoring clinical trial NCT02391233?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02391233 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02391233's enrollment target sits among peer trials
354 57th of 303 higher than 246 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Assessing Peer Support for Physical Activity in Women With HIV and Hypertension
RECRUITING · NA
-
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
- NCT06507618 · 354 participants · Phase 3
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI